EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cyclin B1: A potential prognostic and immunological biomarker in pan-cancer

Quan Chen, Li Ouyang, Qing Liu

Biomolecules and Biomedicine · 2024

DOI: 10.17305/bb.2024.10253 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules and Biomedicine, 2024. Verfasst von Quan Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, China; Hospital Department, Hubei University of Chinese Me…. Hauptthemen laut MEDLINE: Cyclin B1, Biomarkers, Tumor, Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cyclin B1 (CCNB1) encodes a regulatory protein essential for the regulation of cell mitosis, particularly in controlling the G2/M transition phase of the cell cycle. Current research has implicated CCNB1 in the progression of various types of cancer, including gastric cancer, breast cancer, and non-small cell lung cancer. In this study, we conducted a pan-cancer analysis of CCNB1 to investigate its prognostic significance and immunological aspects. Our comprehensive investigation covered a wide range of analyses, including gene expression, promoter methylation, genetic alterations, immune infiltration, immune regulators, and enrichment studies. We utilized multiple databases and tools for this purpose, such as The Cancer Genome Atlas (TCGA), the Genotype-Tissue Expression (GTEx) project, the Human Protein Atlas (HPA), the University of Alabama at Birmingham CANcer data analysis Portal (UALCAN), the Gene Expression Profiling Interactive Analysis (GEPIA), the DNA Methylation Interactive Visualization Database (DNMIVD), the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING), Sangerbox, and cBioPortal. Data analyses were executed using GraphPad Prism software, R software, and various online tools. Our findings demonstrated a significant increase in CCNB1 expression across 28 cancer types. Elevated CCNB1 expression correlated with decreased overall survival (OS) in 11 cancer types and disease-free survival (DFS) in 12 cancer types. Additionally, DNA promoter methylation levels were significantly decreased in 14 cancer types. Furthermore, the study verified a significant association between CCNB1 expression and immune infiltration, immune modulators, microsatellite instability (MSI), and tumor mutational burden (TMB). Enrichment analysis indicated that CCNB1 is involved in multiple cellular pathways. Collectively, our results suggested that CCNB1 has the potential to serve as a valuable prognostic biomarker and may be a promising target for immunotherapy in various cancer types.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclin B1Biomarkers, TumorNeoplasmsHumansPrognosisDNA MethylationGene Expression Regulation, NeoplasticPromoter Regions, Genetic

Substanzen

Cyclin B1Biomarkers, TumorCCNB1 protein, human

Autor:innen und Institutionen

  • Department of Pathology, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, China; Hospital Department, Hubei University of Chinese Medicine, Wuhan, China.

Zitieren

APA

Chen, Q., Ouyang, L., & Liu, Q. (2024). Cyclin B1: A potential prognostic and immunological biomarker in pan-cancer. Biomolecules and Biomedicine. https://doi.org/10.17305/bb.2024.10253

Vancouver

Chen Q, Ouyang L, Liu Q. Cyclin B1: A potential prognostic and immunological biomarker in pan-cancer. Biomolecules and Biomedicine. 2024. doi:10.17305/bb.2024.10253

BibTeX
@article{Chen2024,
  author = {Chen, Quan and Ouyang, Li and Liu, Qing},
  title = {Cyclin B1: A potential prognostic and immunological biomarker in pan-cancer},
  journal = {Biomolecules and Biomedicine},
  year = {2024},
  doi = {10.17305/bb.2024.10253}
}
Kostenlos starten →